A new trading day began on Tuesday, with Taysha Gene Therapies Inc (NASDAQ: TSHA) stock price down -0.18% from the previous day of trading, before settling in for the closing price of $2.79. TSHA’s price has ranged from $1.05 to $4.32 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Meanwhile, its annual earnings per share averaged 9.34%. With a float of $176.26 million, this company’s outstanding shares have now reached $205.05 million.
In an organization with 73 employees, it is important to assess its efficiency. In terms of profitability, gross margin is 72.63%, operating margin of -1225.78%, and the pretax margin is -1201.08%.
Taysha Gene Therapies Inc (TSHA) Insider Updates
As we move forward, let’s examine how large-scale investors are investing in this stock of the Biotechnology Industry. The insider ownership of Taysha Gene Therapies Inc is 17.89%, while institutional ownership is 75.84%. The most recent insider transaction that took place on May 30 ’25, was worth 2,062,500. In this transaction 10% Owner of this company bought 750,000 shares at a rate of $2.75, taking the stock ownership to the 2,841,704 shares. Before that another transaction happened on Jun 27 ’24, when Company’s 10% Owner bought 1,333,333 for $2.25, making the entire transaction worth $2,999,999. This insider now owns 1,333,333 shares in total.
Taysha Gene Therapies Inc (TSHA) Performance Highlights and Predictions
According to the Wall Street analysts, stocks earnings will be around 9.34% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 11.90% during the next five years compared to -63.99% drop over the previous five years of trading.
Taysha Gene Therapies Inc (NASDAQ: TSHA) Trading Performance Indicators
Here are Taysha Gene Therapies Inc’s current performance indicators. According to the last quarter’s results, the stock had a quick ratio of 5.35. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 100.70.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.36, a number that is poised to hit -0.08 in the next quarter and is forecasted to reach -0.38 in one year’s time.
Technical Analysis of Taysha Gene Therapies Inc (TSHA)
Let’s dig in a bit further. During the last 5-days, its volume was 7.89 million. That was better than the volume of 2.81 million it reported in year-ago period. As of the previous 9 days, the stock’s Stochastic %D was 39.79%. Additionally, its Average True Range was 0.25.
During the past 100 days, Taysha Gene Therapies Inc’s (TSHA) raw stochastic average was set at 79.00%, which indicates a significant increase from 52.58% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 78.35% in the past 14 days, which was lower than the 107.02% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $1.98, while its 200-day Moving Average is $1.95. However, in the short run, Taysha Gene Therapies Inc’s stock first resistance to watch stands at $2.91. Second resistance stands at $3.04. The third major resistance level sits at $3.10. If the price goes on to break the first support level at $2.71, it is likely to go to the next support level at $2.65. Assuming the price breaks the second support level, the third support level stands at $2.52.
Taysha Gene Therapies Inc (NASDAQ: TSHA) Key Stats
With a market capitalization of 727.05 million, the company has a total of 214,662K Shares Outstanding. Currently, annual sales are 8,330 K while annual income is -89,300 K. The company’s previous quarter sales were 2,300 K while its latest quarter income was -21,530 K.
